Blog

Introduction PK and ADA assays developed for a bispecific monoclonal antibody were built using atypical assay formats and non-standard bioanalytical methods and reagents. When those reagents were transferred to the facility responsible for the in-life portion of the preclinical tox study, validation failed despite repeated attempts. Timelines for filing with the regulatory agency began to…